Prostate Cancer News & Features
The anticancer drug galeterone has proved successful in lowering prostate-specific antigen levels in men with castration-resistant prostate cancer (CRPC).
Men receiving hormone therapy for prostate cancer may be missing out on protective meds, researchers say.
A new anticancer drug, already in clinical development, may help spare healthy cells from the effects of radiation treatments.
A genetic test has been developed to identify which men are at higher risk for prostate cancer recurrence after localized treatment with surgery or radiotherapy.
Phosphorous is independently associated with the risk of developing lethal and high-grade prostate cancer.
Prostate Cancer Videos
- Ovarian cancer patients may benefit from pelvic radiotherapy
- Added sugars may increase blood pressure more than high salt consumption
- Researchers identify biological indicator of response to new ovarian cancer drug
- Evolving roles for oncology nurses: Biospecimen collection
- Key discovery in understanding successes and failures of immunotherapy
- Utilizing home therapy for cancer-related lymphedema can lower costs
- Drug combination produces good response rates in advanced papillary renal cell carcinoma (pRCC)
- Breast cancer and pregnancy: Overlapping of two disciplines
- IDH1 mutation inhibitor first to demonstrate anticancer activity
- Wide variation exists in the quality and content of clinical cancer guidelines
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|